The following is a summary of “Treating chronic kidney disease in Danish primary care: results from the observational ATLAS study,” published in the February 2025 issue of BMC Primary Care by ...

Lack of steady income can cause patients to face difficulties in bearing treatment costs that can reach up to RM40,000 a year ...

AstraZeneca will gain full rights for roxadustat in China where it is approved to treat anaemia seen with chronic kidney ...

Devendra Barlewar, a scientist from the Union Ministry of Defence, successfully underwent his third kidney transplant.

If validated prospectively, the findings could be ‘transformative’ for patients with no current medical options.

AstraZeneca is paying $160 million for FibroGen’s China business, giving the U.K.-based Big Pharma the regional rights to ...

The prevention of multiple long term conditions needs to be higher up the healthcare agenda and for this to happen we need to be more precise about what we mean when talking about it. As populations ...

AstraZeneca walked away from the bulk of its roxadustat partnership with FibroGen—though the pharma at the time decided to ...

I’ve had acid reflux problems all of my life. I had to have Rolaids in my pocket until my primary care doctor prescribed ...

FibroGen sells its China unit to AstraZeneca for $160 million, extending its cash runway into 2027 and advancing its ...

AstraZeneca will obtain the full rights to Roxadustat in China, FibroGen said, adding that it will retain the US and other ...